Results of questionnaire on decision-making to treat advanced non-small cell lung cancer based on American and European practical guidelines

Yuichiro Takeda, Katsuhiko Naoki, Kenzo Soejima, Toshinori Kanemura, Seisuke Nagase, Tatsuo Ohhira, Norihiko Ikeda

Research output: Contribution to journalArticle

Abstract

During 2009, practical routine guidelines for advanced non-small cell lung cancer used in Europe or USA were updated because the clinical benefits of molecular target agents were confirmed through several pivotal clinical trials. These molecular target agents appeared in guidelines which became available in Japan by the end of 2009. We made a questionnaire for decision-making to treat advanced non-small cell lung cancer based on these practical guidelines. Oncologists of lung cancer working in the Shinjuku area of Tokyo in Japan were eligible. Between March 15th and April 9th in 2010, 28 oncologists from 12 departments in 7 hospitals completed this questionnaire. Most of them made the global standard decision-making according to the new guidelines, including new proposals such as usage of epidermal growth factor receptor-tyrosine kinase inhibitors. There were 3 differences from the guidelines. 1) Platinum doublets were selected even in 2nd- or 3rd-line treatment because of the expected tumor shrinkage. 2) Single cytotoxic agents were selected even for 3rd-line treatment. The tendency of a backward shift in decision-making was observed. 3) There were few selections of regimens including bevacizumab because of medical systems such as DPC (Diagnosis Procedure Combination) that is Japanese DRG (Diagnosis-Related Group)/PPS (Prospective Payment System).

Original languageEnglish
Pages (from-to)225-231
Number of pages7
JournalJapanese Journal of Cancer and Chemotherapy
Volume38
Issue number2
Publication statusPublished - 2011 Feb

Fingerprint

Non-Small Cell Lung Carcinoma
Decision Making
Guidelines
Japan
Prospective Payment System
Tokyo
Diagnosis-Related Groups
Cytotoxins
Platinum
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Lung Neoplasms
Surveys and Questionnaires
Clinical Trials
Therapeutics
Neoplasms
Oncologists

Keywords

  • Backward shift of decision-making
  • Guideline
  • Questionnaire

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Results of questionnaire on decision-making to treat advanced non-small cell lung cancer based on American and European practical guidelines. / Takeda, Yuichiro; Naoki, Katsuhiko; Soejima, Kenzo; Kanemura, Toshinori; Nagase, Seisuke; Ohhira, Tatsuo; Ikeda, Norihiko.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 38, No. 2, 02.2011, p. 225-231.

Research output: Contribution to journalArticle

Takeda, Yuichiro ; Naoki, Katsuhiko ; Soejima, Kenzo ; Kanemura, Toshinori ; Nagase, Seisuke ; Ohhira, Tatsuo ; Ikeda, Norihiko. / Results of questionnaire on decision-making to treat advanced non-small cell lung cancer based on American and European practical guidelines. In: Japanese Journal of Cancer and Chemotherapy. 2011 ; Vol. 38, No. 2. pp. 225-231.
@article{0fd952dcbd6146b28b55088ed95cb9c3,
title = "Results of questionnaire on decision-making to treat advanced non-small cell lung cancer based on American and European practical guidelines",
abstract = "During 2009, practical routine guidelines for advanced non-small cell lung cancer used in Europe or USA were updated because the clinical benefits of molecular target agents were confirmed through several pivotal clinical trials. These molecular target agents appeared in guidelines which became available in Japan by the end of 2009. We made a questionnaire for decision-making to treat advanced non-small cell lung cancer based on these practical guidelines. Oncologists of lung cancer working in the Shinjuku area of Tokyo in Japan were eligible. Between March 15th and April 9th in 2010, 28 oncologists from 12 departments in 7 hospitals completed this questionnaire. Most of them made the global standard decision-making according to the new guidelines, including new proposals such as usage of epidermal growth factor receptor-tyrosine kinase inhibitors. There were 3 differences from the guidelines. 1) Platinum doublets were selected even in 2nd- or 3rd-line treatment because of the expected tumor shrinkage. 2) Single cytotoxic agents were selected even for 3rd-line treatment. The tendency of a backward shift in decision-making was observed. 3) There were few selections of regimens including bevacizumab because of medical systems such as DPC (Diagnosis Procedure Combination) that is Japanese DRG (Diagnosis-Related Group)/PPS (Prospective Payment System).",
keywords = "Backward shift of decision-making, Guideline, Questionnaire",
author = "Yuichiro Takeda and Katsuhiko Naoki and Kenzo Soejima and Toshinori Kanemura and Seisuke Nagase and Tatsuo Ohhira and Norihiko Ikeda",
year = "2011",
month = "2",
language = "English",
volume = "38",
pages = "225--231",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "2",

}

TY - JOUR

T1 - Results of questionnaire on decision-making to treat advanced non-small cell lung cancer based on American and European practical guidelines

AU - Takeda, Yuichiro

AU - Naoki, Katsuhiko

AU - Soejima, Kenzo

AU - Kanemura, Toshinori

AU - Nagase, Seisuke

AU - Ohhira, Tatsuo

AU - Ikeda, Norihiko

PY - 2011/2

Y1 - 2011/2

N2 - During 2009, practical routine guidelines for advanced non-small cell lung cancer used in Europe or USA were updated because the clinical benefits of molecular target agents were confirmed through several pivotal clinical trials. These molecular target agents appeared in guidelines which became available in Japan by the end of 2009. We made a questionnaire for decision-making to treat advanced non-small cell lung cancer based on these practical guidelines. Oncologists of lung cancer working in the Shinjuku area of Tokyo in Japan were eligible. Between March 15th and April 9th in 2010, 28 oncologists from 12 departments in 7 hospitals completed this questionnaire. Most of them made the global standard decision-making according to the new guidelines, including new proposals such as usage of epidermal growth factor receptor-tyrosine kinase inhibitors. There were 3 differences from the guidelines. 1) Platinum doublets were selected even in 2nd- or 3rd-line treatment because of the expected tumor shrinkage. 2) Single cytotoxic agents were selected even for 3rd-line treatment. The tendency of a backward shift in decision-making was observed. 3) There were few selections of regimens including bevacizumab because of medical systems such as DPC (Diagnosis Procedure Combination) that is Japanese DRG (Diagnosis-Related Group)/PPS (Prospective Payment System).

AB - During 2009, practical routine guidelines for advanced non-small cell lung cancer used in Europe or USA were updated because the clinical benefits of molecular target agents were confirmed through several pivotal clinical trials. These molecular target agents appeared in guidelines which became available in Japan by the end of 2009. We made a questionnaire for decision-making to treat advanced non-small cell lung cancer based on these practical guidelines. Oncologists of lung cancer working in the Shinjuku area of Tokyo in Japan were eligible. Between March 15th and April 9th in 2010, 28 oncologists from 12 departments in 7 hospitals completed this questionnaire. Most of them made the global standard decision-making according to the new guidelines, including new proposals such as usage of epidermal growth factor receptor-tyrosine kinase inhibitors. There were 3 differences from the guidelines. 1) Platinum doublets were selected even in 2nd- or 3rd-line treatment because of the expected tumor shrinkage. 2) Single cytotoxic agents were selected even for 3rd-line treatment. The tendency of a backward shift in decision-making was observed. 3) There were few selections of regimens including bevacizumab because of medical systems such as DPC (Diagnosis Procedure Combination) that is Japanese DRG (Diagnosis-Related Group)/PPS (Prospective Payment System).

KW - Backward shift of decision-making

KW - Guideline

KW - Questionnaire

UR - http://www.scopus.com/inward/record.url?scp=79957542241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957542241&partnerID=8YFLogxK

M3 - Article

C2 - 21368485

AN - SCOPUS:79957542241

VL - 38

SP - 225

EP - 231

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 2

ER -